ELI LILLY & Co (LLY): who owns it and who trades it
As of Nov 13, 2026, LLY insiders reported 121 open-market sales worth $1.1B and no purchases in the last 12 months, with 2% of the sale value made under pre-set 10b5-1 plans. The largest seller was Lilly Endowment Inc (10% owner), with $1.1B. 13 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 13, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Eli Lilly
From the latest filingsOverall: about as much buying as selling. Insiders and Congress mostly sold. Funds mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns LLY
4,592 funds and institutions reported LLY shares worth $941B at the end of Q2 2026, about 83% of the company. The largest holder is Lilly Endowment Inc with 9.6%.
Funds and institutions (13F) 83%Everyone else 17%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Lilly Endowment Inc | 90.38M | 9.60% | $108B | -2% |
| BlackRock, Inc. | 67.54M | 7.17% | $81B | +2% |
| Vanguard Capital Management LLC | 53.53M | 5.68% | $64.2B | +0% |
| PNC Financial Services Group, Inc. | 51.32M | 5.45% | $61.6B | No change |
| State Street Corp | 36.22M | 3.85% | $43.4B | +2% |
| FMR LLC (Fidelity) | 28.46M | 3.02% | $34.1B | +8% |
| Capital Research Global Investors | 20.87M | 2.22% | $25B | -15% |
| Vanguard Portfolio Management LLC | 20.86M | 2.21% | $25B | -1% |
| Geode Capital Management, LLC | 20.31M | 2.16% | $24.3B | +1% |
| Morgan Stanley | 16.23M | 1.72% | $19.5B | +5% |
| Capital World Investors | 15.90M | 1.69% | $19.1B | +2% |
| T. Rowe Price Associates | 13.91M | 1.48% | $16.7B | -1% |
| JPMorgan Chase & Co | 12.60M | 1.34% | $15.5B | – |
| Norges Bank | 11.47M | 1.22% | $13.8B | – |
| Bank of America Corp | 11.27M | 1.20% | $13.5B | +1% |
| Wellington Management Group LLP | 11.00M | 1.17% | $13.2B | -18% |
| State Farm Mutual Automobile Insurance Co | 10.76M | 1.14% | $12.9B | No change |
| Primecap Management Co | 9.17M | 0.97% | $11B | -1% |
| Northern Trust Corp | 8.80M | 0.93% | $10.6B | -0% |
| Goldman Sachs Group Inc | 7.65M | 0.81% | $9.2B | +21% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, LLY insiders reported $0 of open-market purchases and $1.1B of sales. 2% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | Anat Hakim | Vice president | Sale plan | 5,000 | $1,402.52 | $7M | Form 4 |
| Aug 17, 2026 | Patrik Jonsson | Vice president | Sale plan | 6,500 | $1,175.10 | $7.6M | Form 4 |
| Aug 10, 2026 | Donald A Zakrowski | Vice president | Sale plan | 2,000 | $1,185.01 | $2.4M | Form 4 |
| Aug 7, 2026 | Anat Hakim | Vice president | Sale plan | 5,000 | $1,190.00 | $6M | Form 4 |
| Jun 10, 2026 | Ilya Yuffa | Vice president | Sale plan | 2,500 | $1,150.77 | $2.9M | Form 4 |
| May 6, 2026 | Lilly Endowment Inc | Other | Sale | 2,208 | $996.18 | $2.2M | Form 4 |
| May 6, 2026 | Lilly Endowment Inc | Other | Sale | 13,620 | $995.23 | $13.6M | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 930 | $1,088.97 | $1M | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 3,575 | $1,090.18 | $3.9M | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 1,224 | $1,091.05 | $1.3M | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 1,072 | $1,092.56 | $1.2M | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 1,322 | $1,093.58 | $1.4M | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 420 | $1,094.70 | $460K | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 475 | $1,095.74 | $520K | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 6,408 | $1,097.41 | $7M | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 9,573 | $1,098.55 | $10.5M | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 20,447 | $1,099.36 | $22.5M | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 14,937 | $1,100.46 | $16.4M | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 20,668 | $1,101.42 | $22.8M | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 34,434 | $1,102.41 | $38M | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 40,956 | $1,103.31 | $45.2M | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 21,042 | $1,104.40 | $23.2M | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 24,362 | $1,105.46 | $26.9M | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 13,701 | $1,106.42 | $15.2M | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 16,650 | $1,107.37 | $18.4M | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 13,247 | $1,108.42 | $14.7M | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 8,513 | $1,109.32 | $9.4M | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 3,464 | $1,110.37 | $3.8M | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 2,085 | $1,111.21 | $2.3M | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 4,652 | $1,112.43 | $5.2M | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 9,053 | $1,113.77 | $10.1M | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 4,342 | $1,114.37 | $4.8M | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 2,210 | $1,115.76 | $2.5M | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 2,737 | $1,116.69 | $3.1M | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 1,070 | $1,087.80 | $1.2M | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 895 | $1,085.11 | $971K | Form 4 |
| Jan 7, 2026 | Lilly Endowment Inc | 10% owner | Sale | 7,684 | $1,086.75 | $8.4M | Form 4 |
| Jan 5, 2026 | Lilly Endowment Inc | 10% owner | Sale | 1,390 | $1,085.01 | $1.5M | Form 4 |
| Dec 29, 2025 | Lilly Endowment Inc | 10% owner | Sale | 3,593 | $1,085.04 | $3.9M | Form 4 |
| Dec 24, 2025 | Lilly Endowment Inc | 10% owner | Sale | 2,629 | $1,085.17 | $2.9M | Form 4 |
| Dec 23, 2025 | Lilly Endowment Inc | 10% owner | Sale | 240 | $1,085.04 | $260K | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 9,249 | $1,109.45 | $10.3M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 5,043 | $1,108.71 | $5.6M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 1,340 | $1,110.53 | $1.5M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 1,260 | $1,079.37 | $1.4M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 651 | $1,080.73 | $704K | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 1,606 | $1,081.90 | $1.7M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 160 | $1,082.93 | $173K | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 3,069 | $1,084.70 | $3.3M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 5,604 | $1,086.07 | $6.1M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 6,508 | $1,086.94 | $7.1M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 5,589 | $1,087.97 | $6.1M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 5,284 | $1,088.91 | $5.8M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 1,907 | $1,089.85 | $2.1M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 7,794 | $1,107.48 | $8.6M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 18,254 | $1,092.06 | $19.9M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 9,050 | $1,093.16 | $9.9M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 6,246 | $1,094.03 | $6.8M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 2,083 | $1,094.79 | $2.3M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 1,061 | $1,096.33 | $1.2M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 4,198 | $1,097.44 | $4.6M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 4,639 | $1,098.32 | $5.1M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 6,545 | $1,099.49 | $7.2M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 8,527 | $1,100.34 | $9.4M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 11,854 | $1,101.45 | $13.1M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 7,456 | $1,102.35 | $8.2M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 6,274 | $1,103.58 | $6.9M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 5,196 | $1,104.41 | $5.7M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 2,494 | $1,105.32 | $2.8M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 3,662 | $1,106.57 | $4.1M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 800 | $1,077.99 | $862K | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 882 | $1,076.00 | $949K | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 2,481 | $1,073.74 | $2.7M | Form 4 |
| Nov 25, 2025 | Lilly Endowment Inc | 10% owner | Sale | 5,927 | $1,091.12 | $6.5M | Form 4 |
| Nov 24, 2025 | Lilly Endowment Inc | 10% owner | Sale | 744 | $1,072.78 | $798K | Form 4 |
| Nov 24, 2025 | Lilly Endowment Inc | 10% owner | Sale | 2,954 | $1,073.60 | $3.2M | Form 4 |
| Nov 24, 2025 | Lilly Endowment Inc | 10% owner | Sale | 14,105 | $1,069.48 | $15.1M | Form 4 |
| Nov 24, 2025 | Lilly Endowment Inc | 10% owner | Sale | 120,016 | $1,068.18 | $128M | Form 4 |
| Nov 24, 2025 | Lilly Endowment Inc | 10% owner | Sale | 1,710 | $1,071.37 | $1.8M | Form 4 |
| Nov 24, 2025 | Lilly Endowment Inc | 10% owner | Sale | 2,778 | $1,070.35 | $3M | Form 4 |
| Nov 21, 2025 | Lilly Endowment Inc | 10% owner | Sale | 9,871 | $1,050.27 | $10.4M | Form 4 |
| Nov 21, 2025 | Lilly Endowment Inc | 10% owner | Sale | 5,506 | $1,051.48 | $5.8M | Form 4 |
| Nov 21, 2025 | Lilly Endowment Inc | 10% owner | Sale | 160 | $1,066.15 | $171K | Form 4 |
| Nov 21, 2025 | Lilly Endowment Inc | 10% owner | Sale | 2,885 | $1,052.36 | $3M | Form 4 |
| Nov 21, 2025 | Lilly Endowment Inc | 10% owner | Sale | 1,987 | $1,053.46 | $2.1M | Form 4 |
| Nov 21, 2025 | Lilly Endowment Inc | 10% owner | Sale | 1,629 | $1,054.42 | $1.7M | Form 4 |
| Nov 21, 2025 | Lilly Endowment Inc | 10% owner | Sale | 2,495 | $1,055.45 | $2.6M | Form 4 |
| Nov 21, 2025 | Lilly Endowment Inc | 10% owner | Sale | 1,546 | $1,056.40 | $1.6M | Form 4 |
| Nov 21, 2025 | Lilly Endowment Inc | 10% owner | Sale | 5,064 | $1,057.58 | $5.4M | Form 4 |
| Nov 21, 2025 | Lilly Endowment Inc | 10% owner | Sale | 9,729 | $1,058.46 | $10.3M | Form 4 |
| Nov 21, 2025 | Lilly Endowment Inc | 10% owner | Sale | 23,916 | $1,059.66 | $25.3M | Form 4 |
| Nov 21, 2025 | Lilly Endowment Inc | 10% owner | Sale | 7,582 | $1,060.53 | $8M | Form 4 |
| Nov 21, 2025 | Lilly Endowment Inc | 10% owner | Sale | 10,492 | $1,061.56 | $11.1M | Form 4 |
| Nov 21, 2025 | Lilly Endowment Inc | 10% owner | Sale | 9,051 | $1,062.52 | $9.6M | Form 4 |
| Nov 21, 2025 | Lilly Endowment Inc | 10% owner | Sale | 8,576 | $1,063.57 | $9.1M | Form 4 |
| Nov 21, 2025 | Lilly Endowment Inc | 10% owner | Sale | 3,378 | $1,064.43 | $3.6M | Form 4 |
| Nov 21, 2025 | Lilly Endowment Inc | 10% owner | Sale | 1,459 | $1,065.57 | $1.6M | Form 4 |
| Nov 20, 2025 | Lilly Endowment Inc | 10% owner | Sale | 6,701 | $1,051.37 | $7M | Form 4 |
| Nov 20, 2025 | Lilly Endowment Inc | 10% owner | Sale | 3,188 | $1,054.51 | $3.4M | Form 4 |
| Nov 20, 2025 | Lilly Endowment Inc | 10% owner | Sale | 16,845 | $1,050.36 | $17.7M | Form 4 |
Latest 100 of 121 trades in the last 12 months.
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Lilly Endowment Inc | 10% owner | – | $1.1B | May 6, 2026 |
| Anat Hakim | EVP, GC & Secretary | – | $13M | Nov 2, 2026 |
| Patrik Jonsson | EVP & President, LLY Int'l | – | $7.6M | Aug 17, 2026 |
| Ilya Yuffa | EVP&Pres, LLY USA&Global Capab | – | $2.9M | Jun 10, 2026 |
| Donald A Zakrowski | SVP, Finance, & CAO | – | $2.4M | Aug 10, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
LLY short interest
Low short interest. 0.8% of LLY shares are sold short: about 1 share in 130. Over the last 12 reports the number of shares short went down 14%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 7.21M LLY shares were sold short, 0.8% of the shares outstanding, up 3.6% from the report before. At the average daily volume of 2.71M shares, buying them all back would take about 2.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 7.21M | 0.77% | +4% | 2.71M | 2.7 |
| Oct 15, 2026 | 6.96M | 0.74% | -1% | 2.29M | 3.0 |
| Sep 30, 2026 | 7.04M | 0.75% | -6% | 2.40M | 2.9 |
| Sep 15, 2026 | 7.52M | 0.80% | -5% | 2.20M | 3.4 |
| Aug 31, 2026 | 7.89M | 0.84% | +20% | 2.64M | 3.0 |
| Aug 14, 2026 | 6.56M | 0.70% | -28% | 3.11M | 2.1 |
| Jul 31, 2026 | 9.12M | 0.97% | -11% | 2.32M | 3.9 |
| Jul 15, 2026 | 10.28M | 1.09% | +10% | 2.53M | 4.1 |
| Jun 30, 2026 | 9.35M | 0.99% | -3% | 3.62M | 2.6 |
| Jun 15, 2026 | 9.66M | 1.03% | -1% | 3.21M | 3.0 |
| May 29, 2026 | 9.80M | 1.04% | +16% | 3.31M | 3.0 |
| May 15, 2026 | 8.43M | 0.90% | +7% | 3.33M | 2.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded LLY
Since Nov 16, 2024, 21 members of Congress reported 24 purchases and 41 sales of LLY. The latest was a sale by David J. Taylor on Nov 3, 2026, reported Nov 12, 2026.
Purchases 24Sales 41
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Nov 3, 2026 | David J. Taylor (R-OH) | Sale | $1K–$15K | Self | Nov 12, 2026 | Report |
| Oct 20, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Nov 10, 2026 | Report |
| Jul 10, 2026 | Dan Newhouse (R-WA) | Partial sale | $1K–$15K | Spouse | Jul 17, 2026 | Report |
| Jul 1, 2026 | Michael A. Rulli (R-OH) | Sale | $1K–$15K | Self | Aug 7, 2026 | Report |
| Jun 10, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $50K–$100K | Self | Jul 2, 2026 | Report |
| Apr 14, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | May 8, 2026 | Report |
| Apr 8, 2026 | Lizzie Fletcher (D-TX) | Partial sale | $1K–$15K | Self | May 1, 2026 | Report |
| Apr 2, 2026 | Byron Donalds (R-FL) | Purchase | $1K–$15K | Spouse | May 13, 2026 | Report |
| Apr 2, 2026 | Byron Donalds (R-FL) | Purchase | $1K–$15K | Self | May 13, 2026 | Report |
| Mar 27, 2026 | Alan Armstrong (R-OK) | Sale | $1K–$15K | Self | Jul 21, 2026 | Report |
| Mar 13, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Partial sale | $1K–$15K | Self | Apr 7, 2026 | Report |
| Feb 26, 2026 | David J. Taylor (R-OH) | Purchase | $1K–$15K | Self | Mar 6, 2026 | Report |
| Feb 13, 2026 | Angus S. King, Jr. (I-ME) | Sale | $1K–$15K | Spouse | Mar 24, 2026 | Report |
| Feb 9, 2026 | David J. Taylor (R-OH) | Sale | $1K–$15K | Self | Feb 20, 2026 | Report |
| Jan 16, 2026 | David J. Taylor (R-OH) | Sale | $1K–$15K | Self | Feb 2, 2026 | Report |
| Jan 2, 2026 | Michael A. Rulli (R-OH) | Purchase | $1K–$15K | Self | Aug 7, 2026 | Report |
| Dec 29, 2025 | Angus S. King, Jr. (I-ME) | Purchase | $1K–$15K | Spouse | Jan 26, 2026 | Report |
| Dec 18, 2025 | Julie Johnson (D-TX) | Sale | $1K–$15K | Joint | Jan 15, 2026 | Report |
| Dec 10, 2025 | David J. Taylor (R-OH) | Sale | $1K–$15K | Self | Dec 19, 2025 | Report |
| Dec 2, 2025 | Michael A. Rulli (R-OH) | Sale | $1K–$15K | Self | Aug 7, 2026 | Report |
| Nov 21, 2025 | John Boozman (R-AR) | Partial sale | $1K–$15K | Joint | Dec 8, 2025 | Report |
| Nov 18, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Dec 15, 2025 | Report |
| Nov 13, 2025 | Julie Johnson (D-TX) | Partial sale | $1K–$15K | Joint | Dec 11, 2025 | Report |
| Oct 24, 2025 | Shelley Moore Capito (R-WV) | Purchase | $1K–$15K | Spouse | Nov 4, 2025 | Report |
| Sep 23, 2025 | Val T. Hoyle (D-OR) | Sale | $1K–$15K | Spouse | Oct 10, 2025 | Report |
| Aug 22, 2025 | John Boozman (R-AR) | Purchase | $1K–$15K | Joint | Sep 12, 2025 | Report |
| Aug 14, 2025 | Julie Johnson (D-TX) | Partial sale | $1K–$15K | Joint | Sep 11, 2025 | Report |
| Aug 14, 2025 | David J. Taylor (R-OH) | Purchase | $15K–$50K | Self | Sep 2, 2025 | Report |
| Aug 14, 2025 | David J. Taylor (R-OH) | Purchase | $1K–$15K | Self | Sep 2, 2025 | Report |
| Aug 11, 2025 | John Boozman (R-AR) | Purchase | $1K–$15K | Joint | Sep 12, 2025 | Report |
| Jul 16, 2025 | Lisa C. McClain (R-MI) | Sale | $1K–$15K | Spouse | Aug 13, 2025 | Report |
| Jul 10, 2025 | Lisa C. McClain (R-MI) | Purchase | $1K–$15K | Spouse | Aug 13, 2025 | Report |
| Jun 9, 2025 | Lisa C. McClain (R-MI) | Partial sale | $1K–$15K | Spouse | Aug 13, 2025 | Report |
| Jun 3, 2025 | Jonathan L. Jackson (D-IL) | Sale | $15K–$50K | Joint | Jul 14, 2025 | Report |
| May 30, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Partial sale | $1K–$15K | Self | Jun 6, 2025 | Report |
| May 21, 2025 | Jonathan L. Jackson (D-IL) | Sale | $1K–$15K | Spouse | Aug 25, 2025 | Report |
| May 14, 2025 | Marjorie Greene (GA) | Purchase | $1K–$15K | Self | May 19, 2025 | Report |
| May 13, 2025 | Josh Gottheimer (D-NJ) | Partial sale | $1K–$15K | Joint | Jun 11, 2025 | Report |
| May 12, 2025 | Jefferson Shreve (R-IN) | Sale | $100K–$250K | Self | Jun 22, 2025 | Report |
| May 6, 2025 | Val T. Hoyle (D-OR) | Partial sale | $1K–$15K | Spouse | Sep 12, 2025 | Report |
| May 5, 2025 | Marjorie Greene (GA) | Purchase | $1K–$15K | Self | May 6, 2025 | Report |
| May 1, 2025 | Josh Gottheimer (D-NJ) | Purchase | $1K–$15K | Joint | Jun 11, 2025 | Report |
| Apr 23, 2025 | Jonathan L. Jackson (D-IL) | Purchase | $1K–$15K | Spouse | Aug 25, 2025 | Report |
| Apr 21, 2025 | Jonathan L. Jackson (D-IL) | Purchase | $15K–$50K | Joint | May 13, 2025 | Report |
| Apr 21, 2025 | Bruce Westerman (R-AR) | Sale | $1K–$15K | Self | May 12, 2025 | Report |
| Apr 15, 2025 | Tommy Tuberville (R-AL) | Sale | $15K–$50K | Joint | May 15, 2025 | Report |
| Apr 11, 2025 | Dan Newhouse (R-WA) | Partial sale | $1K–$15K | Spouse | May 16, 2025 | Report |
| Apr 9, 2025 | Josh Gottheimer (D-NJ) | Partial sale | $1K–$15K | Joint | May 14, 2025 | Report |
| Apr 8, 2025 | Robert P. Bresnahan, Jr. (R-PA) | Sale | $1K–$15K | Self | Apr 28, 2025 | Report |
| Apr 7, 2025 | Julie Johnson (D-TX) | Sale | $1K–$15K | Joint | May 14, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Eli Lilly company events
Eli Lilly filed 7 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Oct 29, 2026.
- Oct 29, 2026ResultsReleased financial results. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- May 20, 2026AnnouncementEli Lilly and Company completed its offering of $750 million of its Floating Rate Notes due 2028, $500 million of its Floating Rate Notes due 2029 (the “2029 Floating Rate Notes” and, together with the 2028 Floating Rate Notes, the “Floating Rate Notes”), $750 million of its 4.150% Notes due 2029… Filing
- May 7, 2026VoteReported shareholder vote results. Filing
- Apr 30, 2026ResultsReleased financial results. Filing
- Feb 4, 2026ResultsReleased financial results. Filing
- Nov 21, 2025LeadershipReported a change among its top officers or directors, or their pay. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
How Eli Lilly makes money
United States brought in 67% of Eli Lilly's revenue ($43.5B of $65.2B) in 2025. Europe was next, at 18%.
By region, 2025
From Eli Lilly's annual report (10-K) for the year ended Dec 31, 2025, filed Feb 12, 2026. The company chooses how to group its revenue, so the parts differ from one company to the next. Read the filing · How the biggest companies make money
Eli Lilly financials
Famous investors that hold LLY
13 of the 50 well-known investors we track reported holding LLY in their latest 13F filing. The largest position is Ken Fisher's, worth $6.3B.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Fisher · Fisher Asset Management | Q3 2026 | 5.42M | $6.3B | 1.8% | +7% |
| Ken Griffin · Citadel Advisors | Q2 2026 | 945,456 | $1.1B | 0.7% | +291% |
| Jeremy Grantham · GMO | Q3 2026 | 753,925 | $872M | 1.9% | +1% |
| Israel Englander · Millennium Management | Q2 2026 | 182,678 | $219M | 0.2% | -34% |
| Cathie Wood · ARK Investment Management | Q3 2026 | 107,838 | $125M | 0.7% | +40% |
| Ray Dalio · Bridgewater Associates | Q2 2026 | 87,023 | $104M | 0.4% | +23% |
| Larry Robbins · Glenview Capital Management | Q2 2026 | 57,771 | $69.3M | 1.4% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q2 2026 | 30,885 | $37M | 0.2% | -75% |
| George Soros · Soros Fund Management | Q3 2026 | 22,199 | $25.7M | 0.5% | No change |
| Stanley Druckenmiller · Duquesne Family Office | Q2 2026 | 12,380 | $14.8M | 0.3% | New |
| Steve Cohen · Point72 Asset Management | Q2 2026 | 10,476 | $12.6M | 0.0% | -89% |
| Bill Nygren · Harris Associates (Oakmark) | Q2 2026 | 431 | $517K | 0.0% | -4% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 433 | $504K | 0.0% | -98% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named LLY in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 19, 2026 | LILLY ENDOWMENT, INC. | 13G/A | 9.6% |
| Oct 19, 2026 | LILLY ENDOWMENT, INC. | 13G/A | 9.6% |
Questions about ELI LILLY & Co (LLY) stock
Eli Lilly is a drugmaker based in Indianapolis. Its best-known product today is tirzepatide, sold as Mounjaro for type 2 diabetes since May 2022 and as Zepbound for weight management since November 2023.
What is Lilly Endowment?
Lilly Endowment is a private charitable foundation in Indianapolis. J.K. Lilly Sr. and his sons Eli and J.K. Jr. founded it in 1937 with gifts of 17,500 shares of Eli Lilly stock. It has long been the company's largest single shareholder. A filing in July 2026 put its holding at about 9.6% of the company. In November 2025 the rise in Lilly stock pushed its assets past $100 billion, a first for a US private foundation.
The endowment and the company share a name and a history, but they have no legal connection today.
Why is Lilly Endowment listed as an insider?
A holder of more than 10% of a company's stock counts as an insider. It must report its trades on Form 4, just like executives do. That is why the endowment appears in the insider table next to Lilly's officers, labelled "10% owner".
Earlier reports put its stake above that line, for example about 11% in 2024. It has since dipped just under 10%, so the label reflects its history in the filings.
Why does Lilly Endowment sell so much Lilly stock?
The endowment does not explain individual sales in its filings. It has reported sales in many years, for example in 2021 and through 2025 and 2026. A single day often shows several small sales at slightly different prices. Each line is one batch of trades at a weighted average price, not a separate decision.
Because the endowment is a foundation that holds mainly one stock, its sales can be large in dollars even when they are small next to its total stake. Read insider buying vs insider selling for why one seller can dominate the totals.
Who are the other Lilly insiders?
Dave Ricks has been chief executive since January 2017 and chair of the board since June 2017. Many executive sales on this page are marked as made under pre-set Rule 10b5-1 plans, where the dates and amounts are fixed months ahead.
Why is index fund ownership so high?
After the endowment, the largest holders are index and asset managers such as BlackRock, Vanguard and State Street. They hold Lilly mostly because it is one of the largest companies in the S&P 500 and other indexes their funds track. See what institutional ownership means.
Who owns the most LLY stock?
The largest reported owner of ELI LILLY & Co (LLY) is Lilly Endowment Inc, with 9.6% of the company. In total, 4,592 funds and institutions reported holding LLY at the end of Q2 2026, together about 83% of the shares. See the largest owners.
Are LLY insiders buying or selling?
In the last 12 months, LLY insiders reported no open-market purchases and 121 sales worth $1.1B. The latest trade was on Nov 2, 2026. See every trade.
What is the short interest in LLY?
As of Oct 30, 2026, 7.21M LLY shares were sold short, 0.8% of the shares outstanding, up 3.6% from the report before. At the average daily volume of 2.71M shares, buying them all back would take about 2.7 trading days (days to cover). See the history.
Have members of Congress traded LLY?
Yes. 21 members of Congress reported 24 purchases and 41 sales of LLY since Nov 16, 2024. The latest was reported on Nov 12, 2026. See the trades.
How does Eli Lilly make money?
United States brought in 67% of Eli Lilly's revenue ($43.5B of $65.2B) in 2025. Europe was next, at 18%. See the full split.
Which famous investors hold LLY?
13 of the 50 well-known investors we track reported LLY in their latest 13F filing, including Ken Fisher, Ken Griffin, Jeremy Grantham. The largest position is worth $6.3B. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.